Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F
- PMID: 20933614
- DOI: 10.1016/j.autrev.2010.09.025
Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F
Abstract
Autoantibodies to the centromere proteins (CENP), which are major constituents of the primary constriction of metaphase chromosomes, were first described in 1980. In those seminal publications and 30 years of research that have followed, a number of CENP have been identified as autoantibody targets in human diseases. Historically, autoantibodies directed to CENP-A, -B and -C have been considered relatively specific biomarkers for limited cutaneous systemic sclerosis (lcSSc) or the calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia (CREST) syndrome. These autoantibodies, found in up to 40% of SSc sera, can be identified by indirect immunofluorescence (IIF) on a variety of tissue culture cell lines as a discrete speckled staining pattern of both interphase nuclei and metaphase chromatin. Early in the investigation of anti-CENP, it became apparent that some autoantibodies had a similar IIF pattern wherein as cells entered into the cell cycle, speckled staining of the metaphase chromatin could be observed but, unlike conventional CENP staining, interphase nuclei were not stained. Subsequent studies identified one of the targets of these autoantibodies to be CENP-F, a kinesin binding protein essential for completion of the cell cycle. Early clinical studies found that, unlike antibodies to the earlier described CENP, lcSSc rarely expressed anti-CENP-F and approximately 50% of these patients had a malignancy. This review provides a historical perspective of CENP autoantibodies and focuses on an update of the information on CENP-F and their clinical associations.
Copyright © 2010 Elsevier B.V. All rights reserved.
Similar articles
-
High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F.Clin Invest Med. 1997 Oct;20(5):308-19. Clin Invest Med. 1997. PMID: 9336656
-
Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis.Clin Immunol. 1999 Feb;90(2):182-9. doi: 10.1006/clim.1998.4643. Clin Immunol. 1999. PMID: 10080829
-
Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA.Clin Chim Acta. 2011 Oct 9;412(21-22):1937-43. doi: 10.1016/j.cca.2011.06.041. Epub 2011 Jul 5. Clin Chim Acta. 2011. PMID: 21756890
-
Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype.Autoimmun Rev. 2018 Mar;17(3):267-275. doi: 10.1016/j.autrev.2018.01.006. Epub 2018 Jan 31. Autoimmun Rev. 2018. PMID: 29369808 Review.
-
Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin.Autoimmun Rev. 2016 Jan;15(1):102-9. doi: 10.1016/j.autrev.2015.10.001. Epub 2015 Oct 9. Autoimmun Rev. 2016. PMID: 26455561 Review.
Cited by
-
Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease.Medicine (Baltimore). 2016 Jun;95(25):e3931. doi: 10.1097/MD.0000000000003931. Medicine (Baltimore). 2016. PMID: 27336883 Free PMC article.
-
Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays.Mol Cell Proteomics. 2012 Sep;11(9):669-80. doi: 10.1074/mcp.M111.015529. Epub 2012 May 30. Mol Cell Proteomics. 2012. PMID: 22647870 Free PMC article.
-
Clinical and Immunological Features of Anti-centromere Antibody-Positive Primary Sjögren's Syndrome.Rheumatol Ther. 2018 Dec;5(2):499-505. doi: 10.1007/s40744-018-0126-2. Epub 2018 Sep 25. Rheumatol Ther. 2018. PMID: 30255483 Free PMC article.
-
A Monoclonal Antibody to M-Phase Phosphoprotein 1/Kinesin-Like Protein KIF20B.Monoclon Antib Immunodiagn Immunother. 2019 Aug;38(4):162-170. doi: 10.1089/mab.2019.0016. Epub 2019 Jul 16. Monoclon Antib Immunodiagn Immunother. 2019. PMID: 31260385 Free PMC article.
-
Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma.Hereditas. 2023 Jan 13;160(1):1. doi: 10.1186/s41065-023-00262-3. Hereditas. 2023. PMID: 36635779 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources